Depatuxizumab mafodotin

Drug Profile

Depatuxizumab mafodotin

Alternative Names: ABT-414; ABT-414/806

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Jun 2017 AbbVie completes a phase I trial in Glioblastoma (Combination therapy) in USA, Australia and Netherlands (IV) (NCT01800695)
  • 04 Jun 2017 Pooled safety and efficacy analysis data from a phase I trial in Glioblastoma (Recurrent, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 25 Apr 2017 AbbVie initiates an expanded access of depatuxizumab mafodotin for Cancer (NCT03123952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top